Veru (VERU) Profit After Tax (2012 - 2026)
Veru (VERU) posted quarterly Profit After Tax of -$5.3 million for Q4 2025, up 40.39% year-over-year from -$3.8 million in Q4 2024, and down 2238.85% quarter-over-quarter from -$228000.0 in Q3 2025.
Veru (VERU) Profit After Tax (2012 - 2026) Analysis & Trends
Veru (VERU) has reported Profit After Tax for 14 consecutive years, with -$5.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Profit After Tax rose 40.39% year-over-year to -$5.3 million; the TTM figure through Mar 2026 stood at -$5.7 million (up 84.33% YoY), while the FY2025 annual figure was $752498.0, up 101.99% from the prior year.
- Profit After Tax fell to -$5.3 million in Q4 2025 per VERU's latest filing, from -$228000.0 in the prior quarter.
- Across five years, Profit After Tax topped out at -$136465.0 in Q2 2025 and bottomed at -$41.3 million in Q3 2022.
- Historically, Profit After Tax has averaged -$12.4 million across 5 years, with a median of -$8.4 million in 2023.
- Annual changes were most pronounced in 2022 — Profit After Tax sank 861.4% — and 2025, when it jumped 98.76%.
- Veru's Profit After Tax stood at -$6.4 million in 2021, then tumbled by 506.72% to -$38.7 million in 2022, then soared by 78.62% to -$8.3 million in 2023, then fell by 8.09% to -$8.9 million in 2024, then surged by 40.39% to -$5.3 million in 2025.
- Business Quant data shows VERU's Profit After Tax at -$5.3 million in Q4 2025, -$228000.0 in Q3 2025, and -$136465.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.29 Mn |
| Mar 31, 2026 | -2.74 Mn |
| Dec 31, 2025 | -5.33 Mn |
| Sep 30, 2025 | -228,000.00 |
| Jun 30, 2025 | -136,465.00 |
| Mar 31, 2025 | -7.90 Mn |
| Dec 31, 2024 | -8.95 Mn |
| Sep 30, 2024 | -8.53 Mn |
| Jun 30, 2024 | -10.97 Mn |
| Mar 31, 2024 | -10.03 Mn |
| Dec 31, 2023 | -8.28 Mn |
| Sep 30, 2023 | -8.13 Mn |
| Jun 30, 2023 | -12.52 Mn |
| Mar 31, 2023 | -33.79 Mn |
| Dec 31, 2022 | -38.71 Mn |
| Sep 30, 2022 | -41.29 Mn |
| Jun 30, 2022 | -22.20 Mn |
| Mar 31, 2022 | -14.18 Mn |
| Dec 31, 2021 | -6.38 Mn |
| Sep 30, 2021 | -4.29 Mn |